

Author Index—1996

- Abdel-Dayem, HM, 170(ab)
Abdel-Nabi, H, 154(ab), 157(ab), 169(ab)
Abe, Y, 132
Ackermann, RJ, 154(ab), 159(ab), 161(ab)
Adler, LP, 169(ab)
Agarwal, AK, 160(ab)
Agnew, JE, 316
Ahlberg, A, 155(ab)
Akisik, M, 170(ab)
Altenburger, D, 163(ab)
Amoling, RK, 219
Anderson, R, 154(ab)
Andreasson, S, 32
Areed, J, 158(ab), 173(ab)
Arroyo, A, 161(ab)
Arroyo, AJ, 170(ab), 223
Arthur, JH, 314
Ayache, N, 164(ab)
- Babich, JW, 162(ab)
Bacharach, SL, 152(ab), 166(ab)
Baetens, J, 163(ab)
Balinao, A, 158(ab)
Bardfeld, PA, 213
Barker, C, 166(ab)
Barron, TL, 35
Barrow, SA, 156(ab), 162(ab), 170(ab)
Bartlett, M, 152(ab)
Basoglu, T, 112
Baune, DA, 329
Bavaria, G, 152(ab), 168(ab)
Bednarczyk, E, 169(ab)
Bello, S, 158(ab), 173(ab)
Benjamin, C, 168(ab)
Benjamin, E, 152(ab)
Berman, D, 158(ab), 173(ab)
Black, CM, 316
Blasius, K, 171(ab)
Blea-Geis, M, 187(ab)
Blend, MJ, 155(ab)
Blockx, P, 227
Bloe, F, 83, 204, 295
Boldizzar, S, 187(ab)
Boles Ponto, LL, 162(ab)
Bonab, AA, 156(ab)
Borchert, R, 169(ab)
Bowling, D, 183(ab), 184(ab)
Brackman, CA, 187(ab)
Bradley, LA, 159(ab)
Bromfeld, H, 170(ab)
Brostek, W, 170(ab)
Brown, K, 161(ab)
Brown, PH, 69(br)
Brown, TF, 23
Brucer, M, 280
Burney, RJ, 168(ab)
Burns, JB, 170(ab), 223
Burris, T, 162(ab)
Buscombe, JR, 316
- Cabahug, C, 213
Campbell, ML, 172(ab)
Cancroft, ET, 213
Carey, JE, 154(ab)
Carlson, C, 187(ab)
Carlson, K, 183(ab), 184(ab), 186(ab)
Carrasquillo, JA, 166(ab)
Carretta, RF, 171(ab)
Cason, R, 165(ab)
Castronovo, FP, 45
Chang, CW, 163(ab)
Charkes, ND, 161(ab)
Charron, MD, 160(ab)
Chinol, M, 168(ab)
Chodkowski, B, 166(ab)
Chowdhury, S, 186(ab)
Christian, PE, 329
Chu, RYL, 124
Coates, D, 169(ab)
Coleman, RE, 157(ab)
Collins, J, 169(ab)
Combs, MJ, 160(ab)
Conant, R, 157(ab)
Conklin, ER, 213
Cook, W, 184(ab)
Cooper, MD, 23
Corbett, JR, 153(ab)
Corbilla, R, 184(ab)
Coskun, C, 112
Cowell, SF, 336
Crawford, ES, 55
Cronin, V, 157(ab), 169(ab)
Cross, DM, 155(ab), 156(ab), 173(ab), 174(ab)
Cutrone, J, 185(ab)
- Dachille, MA, 163(ab)
Dadparvar, S, 158(ab)
Dale, S, 185(ab)
Dalipaj, MM, 183(ab), 184(ab)
Dao, T, 187(ab)
Das, S, 165(ab)
Datz, FL, 329
Davidhizar, R, 325(ed)
Davis, CM, 152(ab)
Davis, RT, 219
Day, P, 174(ab)
de Man, P, 155(ab)
Declerck, J, 164(ab)
Dehdashii, F, 168(ab)
Deitch, JS, 213
deKemp, R, 184(ab)
DeLaCruz, M, 186(ab)
DeLima, R, 185(ab)
Delvecchio, A, 170(ab)
Demircali, AE, 112
Dennis, C, 171(ab)
Denny, LL, 157(ab)
Depergola, A, 155(ab)
DePuey, E, 158(ab)
Derby, L, 157(ab)
DeRoo, M, 163(ab)
Deutsch, G, 159(ab)
Devous, MD Sr., 159(ab)
Dey, H, 160(ab)
- Dickinson, TW, 204
Diggles, L, 185(ab)
Dilsizian, V, 152(ab)
Dinh, L, 167(ab)
Dowd, SB, 129, 325(ed), 336
Dunnwald, LK, 154(ab)
Duong, Q, 167(ab)
Dwamena, RL, 161(ab)
- Early, M, 159(ab)
Early, P, 83
Early, PJ, 204
Easton, E, 169(ab)
Eckdahl, JM, 55
Eisenberg, B, 100
Elgazzar, AH, 321
Elliott, E, 152(ab)
Elmaleh, DR, 162(ab)
Elmqvist, E, 185(ab)
Emser, D, 169(ab)
Erb, D, 154(ab)
Eshima, D, 162(ab)
Eshima, L, 162(ab)
Etersque, S, 59
Eubig, C, 166(ab)
- Farley, JB, 219
Faulhaber, P, 169(ab)
Faundez, LA, 183(ab)
Feldmar, J, 164(ab)
Feng, T, 160(ab)
Ficaro, EP, 153(ab), 159(ab), 161(ab)
Fiorenza, M, 168(ab)
Fischamn, AJ, 170(ab)
Fischer, S, 160(ab)
Fischman, AJ, 156(ab), 162(ab)
Fisher, R, 161(ab)
Fitz, C, 171(ab)
Flanagan, FL, 168(ab)
Folks, R, 153(ab), 158(ab)
Fraklin, MJ, 27
Freire, JM, 172(ab)
Fry, J, 167(ab)
Fuchs, L, 154(ab)
Fukuda, H, 132
Furst, S, 156(ab)
Futatsubashi, M, 162(ab)
- Gagnon, A, 152(ab), 168(ab)
Galantowicz, P, 157(ab), 169(ab)
Galt, JR, 161(ab)
Garcia, E, 158(ab)
Garcia, EV, 162(ab)
Garrett, J, 183(ab), 184(ab)
Garringer, MA, 232
Garrison, D, 169(ab)
Gerard, SK, 158(ab)
Germano, G, 173(ab)
Gibbons, RJ, 165(ab)
Gibson, DL, 104
Gil-Gomez, K, 187(ab)
Gilbert, S, 268
- Glowniak, JV, 10, 303
Gona, J, 157(ab), 169(ab)
Goodman, MM, 162(ab)
Gordon, BM, 169(ab), 170(ab)
Gordon, L, 169(ab), 170(ab)
Goris, ML, 164(ab)
Greenspan, BS, 342
Groch, MW, 158(ab), 173(ab)
Gross, K, 169(ab)
- Hackett, MT, 166(ab), 27
Hahn, K, 160(ab)
Halkar, RK, 161(ab)
Hamblen, SM, 157(ab)
Hamilton, DR, 69
Hanauske, A-R, 156(ab)
Hardyman, TJ, 186(ab)
Harrison, C, 158(ab)
Hartnett, SD, 154(ab)
Hauser, TM, 161(ab)
Hawk, TC, 157(ab)
Heller, EN, 155(ab)
Heller, GV, 155(ab), 156(ab), 173(ab), 174(ab)
Helton, JD, 35
Hendel, RC, 173(ab)
Heneghan, W, 170(ab)
Herlong, J, 169(ab)
Herold, TJ, 165(ab)
Hertert, RS, 138(br)
Herz, M, 156(ab)
Hevesy, GC de, 273
Hichwa, RD, 162(ab)
Hilson, AJW, 316
Hinkle, GH, 167(ab)
Hirsch, JI, 114
Hitt, JM, 162(ab)
Hobblick, KE, 186(ab)
Hoffman, SR, 160(ab)
Hoh, C, 187(ab)
Holmberg, M, 185(ab)
Homs, CJ, 166(ab), 172(ab), 173(ab)
Hung, JC, 153(ab), 165(ab), 186(ab), 35, 39
Hunt-Mozgala, J, 213
- Ichise, M, 159(ab)
Imai, Y, 167(ab)
- Jacobs, MD, 186(ab)
Jadali, F, 163(ab), 171(ab)
Jamal, R, 184(ab)
Jense, JA, 59
Jolles, PR, 314
Jolly, J, 187(ab)
Jones, ME, 153(ab), 161(ab)
- Kakiuchi, T, 162(ab)
Kalen, JD, 314
Kanai, T, 167(ab)
Kanazawa, M, 167(ab)
Kandatsu, S, 167(ab)
- Kane, DF, 3, 83, 204, 295
Kapadia, K, 158(ab)
Karesh, SM, 154(ab)
Kato, H, 167(ab)
Kavanagh, P, 173(ab)
Kaye, SA, 316
Kempf, JS, 170(ab)
Khalkhali, I, 185(ab)
Khedkar, NY, 198
Kiat, H, 173(ab)
Kimmel, MA, 166(ab), 173(ab)
Kitsiou, AN, 152(ab)
Knight, LC, 161(ab)
Koeppl, JA, 162(ab)
Koga, M, 167(ab)
Kozakai, K, 164(ab)
Krasikova, R, 163(ab)
Krawczynska, E, 153(ab)
Kreis, J, 157(ab)
Krishnamurthy, GT, 157(ab)
Kritzman, JN, 153(ab)
Kuhl, DE, 159(ab)
Kupfer, S, 187(ab)
Kyger-Liskey, M, 187(ab)
- Lageunesse, S, 152(ab)
Laliberte, F, 167(ab)
Lam, RW, 59
Larcher, K, 169(ab)
Lauderman, R, 171(ab)
Lawrence, JH, 270
Leonard, SM, 158(ab)
Leonardi, L, 168(ab)
Levi, H, 155(ab)
Liesure, GP, 169(ab)
Lin, HM, 163(ab)
Liu, HG, 159(ab)
Ljung, B, 32
Lorberboym, M, 230, 321
Lu, LFL, 183(ab)
Lucey, D, 160(ab)
Lumia, F, 171(ab)
- Macey, DJ, 167(ab)
Macha, C, 169(ab)
Machado, M, 321
Mack, DR, 186(ab)
MacMullan, J, 160(ab)
Madras, BK, 162(ab)
Maes, A, 163(ab)
Magoun, S, 166(ab), 169(ab)
Mahoney, DW, 165(ab)
Maniam, S, 162(ab)
Mankoff, DA, 154(ab)
Mann, J, 187(ab)
Mannino, T, 160(ab)
Manthei, D, 163(ab)
Marshall, BJ, 160(ab)
Martinez, CJ, 198
Massler, J, 165(ab)
Masuda, K, 164(ab)
Mathis, CA, 163(ab)
Matsuo, S, 164(ab)
Maurer, AH, 161(ab)

- McBride, JG, 166(ab), 170(ab), 172(ab), 173(ab)
 McEnerney, K, 187(ab)
 McKay, BF, 164(ab), 165(ab)
 McKee, BTA, 183(ab), 184(ab)
 McKuisck, A, 169(ab)
 McMahan, M, 119, 155(ab), 156(ab)
 McMahan, MV, 155(ab), 156(ab), 173(ab), 174(ab)
 Meltzer, P, 162(ab)
 Mento, C, 165(ab)
 Meredith, T, 187(ab)
 Metz, JT, 23
 Milko, DL, 163(ab)
 Miller, M, 161(ab)
 Milton, JG, 23
 Minoshima, S, 159(ab)
 Mintun, MA, 163(ab), 171(ab)
 Miraldi, F, 169(ab)
 Mishkin, F, 184(ab), 185(ab), 187(ab)
 Mistiaen, W, 227
 Mitchell, AK, 184(ab)
 Mohr, WW, 104
 Morey, S, 171(ab)
 Morishita, T, 164(ab)
 Morita, R, 164(ab)
 Morris, S, 155(ab)
 Morrissey, GJ, 245(le)
 Mortelmans, L, 163(ab)
 Mountz, JM, 159(ab)
 Mullan, BP, 165(ab)
 Murphy, D, 171(ab)
 Murphy, KH, 49
 Myers, C, 186(ab)
 Myers, WG, 291

 Naddaf, S, 170(ab)
 Natale, D, 155(ab)
 Neria, A, 152(ab)
 Nishiyama, S, 162(ab)
 Nobesawa, S, 162(ab)
 Noma, K, 164(ab)
 Nuyts, J, 163(ab)

 O'Brien, K, 83
 O'Donnell, JK, 169(ab)

 O'Hara, SM, 157(ab)
 Obranovich, GT, 171(ab)
 Ogata, Y, 132
 Ohnishi, H, 164(ab)
 Omar, WS, 170(ab)
 Oster, ZH, 213
 Otero, E, 172(ab)
 Ouchi, Y, 162(ab)

 Pace, W, 164(ab)
 Packard, A, 174(ab)
 Packard, AB, 219
 Paczolt, E, 171(ab)
 Paganelli, G, 168(ab)
 Pajares, M, 172(ab)
 Pang, W, 104
 Panzini, PJ, 166(ab), 170(ab), 172(ab), 173(ab)
 Parkman, HP, 161(ab)
 Patel, YP, 223
 Patterson, M, 173(ab)
 Payne, A, 159(ab)
 Payne, JK, 159(ab)
 Pechmann, M, 160(ab)
 Peller, PJ, 198
 Perdikaris, N, 27
 Perry, D, 186(ab)
 Pham, HL, 184(ab)
 Piriz, J, 155(ab), 156(ab), 174(ab)
 Pitt, SR, 153(ab)
 Podoloff, DA, 167(ab)
 Polulak, D, 162(ab)
 Pong, E, 187(ab)
 Ponto, LLB, 162(ab)
 Pozderac, RV, 167(ab)
 Prekeges, JL, 100
 Price-Eng, K, 100
 Prisco, G, 168(ab)
 Prudencio, GA, 183(ab)

 Redfern, MG, 153(ab), 165(ab), 186(ab)
 Ricci, A, 187(ab)
 Richmond, JW, 162(ab)
 Romer, W, 156(ab)
 Rose, PA, 153(ab)
 Rosner, N, 155(ab)
 Rossi, B, 159(ab), 160(ab)
 Roy, P, 156(ab), 170(ab)
 Rubin, RH, 170(ab)

 Ruddy, TD, 183(ab), 184(ab)
 Russell, A, 155(ab), 156(ab), 173(ab), 174(ab)
 Russell, K, 158(ab)
 Ruszkiewicz, JA, 163(ab)
 Ryan, A, 172(ab)

 Sahin, M, 112
 Saidi, N, 187(ab)
 San Pedro, EC, 159(ab)
 Sato, T, 132
 Satoh, K, 164(ab)
 Sawyer, MT, 157(ab)
 Schwaiger, M, 156(ab)
 Seibyl, J, 159(ab), 160(ab)
 Seo, IS, 166(ab), 170(ab), 172(ab), 173(ab)
 Shah, JH, 157(ab)
 Shehata, A, 156(ab)
 Shih, WJ, 169(ab)
 Shodavaram, S, 165(ab)
 Shonubi, YI, 166(ab), 170(ab), 172(ab), 173(ab)
 Silagan, G, 173(ab)
 Simon, WE, 124
 Simpson, NR, 163(ab)
 Sims, E, 83, 295
 Sinusas, AJ, 155(ab)
 Siraj, QH, 316
 Sisson, JC, 154(ab)
 Smeltzer, W, 152(ab)
 Smith, EM, 342
 Smith, EO, 160(ab)
 Smith, KF, 166(ab), 170(ab), 172(ab), 173(ab)
 Smith, LG, 171(ab)
 So, BT, 23
 Sodee, DB, 157(ab)
 Sollenbarger, JA, 157(ab)
 Sorenson, JF, 236
 Soya, G, 172(ab)
 Spaulding, SA, 154(ab)
 Spencer, SS, 160(ab)
 Spicer, KM, 169(ab)
 Spies, SM, 158(ab), 164(ab), 165(ab)
 Spies, WG, 158(ab)
 Srinivasan, G, 152(ab)
 Stecker, L, 83
 Steves, AM, 350(br)

 Sugita, J, 164(ab)
 Suhara, T, 167(ab)
 Suzuki, T, 164(ab)
 Swailem, F, 171(ab)
 Swanson, DP, 163(ab)
 Sy, WM, 166(ab), 170(ab), 172(ab), 173(ab)

 Tada, M, 132
 Taillefer, R, 152(ab), 168(ab)
 Takahashi, J, 132
 Takahashi, M, 164(ab)
 Takamiya, Y, 155(ab)
 Takano, M, 164(ab)
 Tatsch, K, 160(ab)
 Taylor, A, 161(ab)
 Teates, CD, 160(ab)
 Tecson, J, 173(ab)
 Thodtmann, R, 156(ab)
 Thomas, KS, 92
 Thompson, RB, 166(ab)
 Thorson, LM, 165(ab)
 Tilkemeier, PL, 172(ab)
 Tomitani, T, 167(ab)
 Towbin, R, 171(ab)
 Townsend, DW, 163(ab)
 Trask, DD, 168(ab)
 Treves, ST, 219
 Tsujii, H, 167(ab)
 Tsukada, H., 162(ab)
 Turkington, TG, 157(ab)
 Turoglu, HT, 170(ab)
 Turpin, S, 168(ab)
 Tuttle, WK, 247(br)

 Ulanski, JS, 219
 Urbain, JL, 161(ab)
 Ushio, T, 164(ab)

 Van den Maegdenbergh, V, 163(ab)
 Van Hee, R, 227
 Van Heertum, RL, 165(ab)
 Van Train, K, 158(ab), 173(ab)
 Vande Streek, PR, 171(ab)
 Vansant, J, 153(ab)
 Vassilyadi, M, 167(ab)
 Velarde, Y, 185(ab)
 Vespie, AW, 242

 Vesselle, H, 169(ab)
 Vielleux, NM, 45
 Vines, DC, 159(ab)

 Wackers, FJT, 155(ab)
 Wada, Y, 167(ab)
 Wahl, RL, 161(ab)
 Waite, SD, 39
 Walsh, TK, 157(ab), 171(ab)
 Wang, TST, 165(ab)
 Wasserstein, GJ, 213
 Watkins, GL, 162(ab)
 Watson, MW, 114
 Wawrzywski, PE, 153(ab)
 Weiland, FL, 171(ab)
 Weitz, JW, 213
 Whatley, M, 166(ab)
 White, MP, 155(ab), 173(ab)
 Whiteley, M, 185(ab)
 Wierzbinski, B, 169(ab)
 Williams, J, 187(ab)
 Winkle, W, 183(ab), 184(ab)
 Wiseman, GA, 165(ab)
 Wisniewski, G, 160(ab)
 Wollenweber, SD, 162(ab)

 Yamada, K, 132
 Yamamura, Y, 164(ab)
 Yamashina, H, 164(ab)
 Yamazaki, J, 164(ab)
 Yeh, SH, 163(ab)
 Yoder, JH, 166(ab)
 Yoshida, K, 167(ab)
 Yoshikawa, K, 167(ab)
 Yoshioka, H, 167(ab)
 Yoshioka, S, 132

 Zempel, S, 154(ab)
 Ziegler, S, 156(ab)
 Zimmer, AM, 164(ab), 165(ab)
 Zubal, GI, 155(ab)
 Zubal, IG, 160(ab)
 Zuger, J, 169(ab)

Subject Index—1996

- Acceptance testing**
evaluation of alignment, multihead SPECT imaging, quality control, 314
guidelines for purchasing equipment, bid specifications, 295
- Accuracy**, in dose calibrator performance, quality control testing, 124
- Adenomas**, parathyroid, simultaneous dual isotope imaging, 184(ab)
- ALARA**, *See* As low as reasonably achievable.
- Angiography**, Tc-99m total-body, dual detector gamma camera, 173(ab)
- Arbutamine**, infusion, exercise stress versus, Tc-99m sestamibi uptake comparison, 183(ab)
- Artifacts**
nonuniformity intrinsic flood, point source syringe needle and, 166(ab)
reduction, whole-body FDG-PET imaging enhancements and, techniques, 169(ab)
- As low as reasonable achievable**, determining optimal pediatric dosage, nuclear medicine diagnostics, 35
- Attenuation correction**
brain SPECT, simultaneous acquisition of transmission and emission data, 160(ab)
comparison with and without, F-18 FDG-PET whole-body studies, 157(ab)
Gd-153 myocardial SPECT, effect by Tc-99m increased hepatic activity, 156(ab)
Gd-153 myocardial SPECT, effect of gated acquisition, 173(ab)
inferior wall artifact, increase hepatic activity and, 156(ab)
myocardial perfusion SPECT, 180° versus 360° reconstructions, 153(ab)
nonuniform, Tc-99m MAA perfusion lung SPECT, 161(ab)
Tc-99m cardiac perfusion, effect on defect extent and severity, 153(ab)
- Autoantibodies**, pathogens and, primate circulation clearance, radionuclide imaging, bispecific-based therapies, 188(ab)
- Automated synthesis**, F-18 FDG, volatile losses, 162(ab)
- Bar code verification system**, patient and sample identification for blood radiology, 39
- Becquerel, Henry**, accomplishments of, Marie Curie and her contemporaries, 273
- Biassay**, calculation and prevention of radionuclide intake, gases and volatile substances, NRC's rules and regulations, Part 20, 204
- Bid specifications**, guidelines for purchasing equipment, gamma cameras, 295
- Binding rate**, effect of cisplatin on renal uptake of ^{99m}Tc-MDP, rats, 132
- Biodistribution**
C-11 β-CNT PET, in mice, 184(ab)
C-11 MTRB, in rats, 184(ab)
- Blood flow**
cerebral SPECT CNS Lyme disease assessment, 159(ab)
coregistration of overlaid MRI images, epileptic seizure foci localization, 160(ab)
statistical mapping by three-dimensional stereotactic surface projection, 159(ab)
- Blood-pool imaging**
gated SPECT, planar studies, 152(ab)
radionuclide venogram and, Tc-99m P280, complementary role to thrombo scintigram, 157(ab)
Tc-99m MDP, value for delayed total-body bone scans, 160(ab)
- Boa constrictor**, nuclear medicine's humble beginnings, discoveries of William Prout and others, 280
- Body surface area**, determining optimal pediatric dosage, diagnostic nuclear medicine procedure, 35
- Body weight**, determining optimal pediatric dosage, nuclear medicine diagnostics, 35
- Bohr, Niels**, accomplishments of, Marie Curie and her contemporaries, 273
- Bone**
delayed total-body scan, total-body blood-pool acquisition, Tc-99m MDP, 160(ab)
imaging, PSA test and, prostate cancer diagnosis, 169(ab)
scintigraphy, optimal, 160(ab)
SPECT, 180° versus 360°, faster acquisition, 184(ab)
- Bone imaging technique**, neck angulation and cervical spine straightening for effective cervical spine SPECT, 100
- Bone scintigraphy**, effect of cisplatin on renal uptake in rats, ^{99m}Tc-MDP, 132
- Book Reviews**
Dose Limits for Individuals Who Receive Exposure from Radionuclide Therapy Patients, NCRP Commentary No. 11, 247
Maintenance and Repair of Laboratory, Diagnostic Imaging and Hospital Equipment, 138
Principles of Nuclear Medicine, 2nd edition, 350
Radiation Science and Societal Decision Making, 69
Scientist Experimental Data-Fitting Software, 69
- Bowel**, persistent ⁶⁷Ga-citrate activity, simulation of cholecystitis in case report, 230
- Brain**
FDG-PET, benefits of three-dimensional acquisition, pediatrics, 157(ab)
SPECT, differential magnification during acquisition, 159(ab)
- Breast**
benign/pre-malignant/malignant conditions, region of interest analysis differentiation, 154(ab)
cancer
diagnosis, Tc-99m sestamibi, 187(ab)
diagnostic value of ²⁰¹Tl scintimammography, lateral decubitus positioning, 213
imaging, Tc-99m labeled synthetic peptide and Tc-99m MDP, acquisition protocol, 168(ab)
scintigraphy as adjunctive diagnostic tool, ^{99m}Tc-MIBI, 198
Tc-99m sestamibi, semi-quantitative analysis, utility and reproducibility, 154(ab)
- Camera performance**, guidelines for purchasing equipment, bid specifications, acceptance testing, 295
- Camera purchasing**, guidelines for purchasing equipment, bid specifications, 295
- Carbon-11**, distribution, PET, autoactivation of C-12 beams in heavy ion therapy, 167(ab)
- Carbon-11 acetic acid**, robotic synthesis, 163(ab)
- Carbon-11 β-CNT**, PET, biodistribution in mice, 183(ab)
- Carbon-11 MTRB**, biodistribution, rats, 184(ab)
- Carbon-14 urea**, breath test, low-dose, *H. pylori* detection, 160(ab)
- Cardiac imaging**, extra-cardiac uptake of ^{99m}Tc-MIBI, normal and abnormal variants, 103
- Cervical spine**, effective SPECT imaging, ANG versus HOR technique, 100
- Chemical substance use**, pilot study of health problems among radiologic science professionals, 59
- Chemotherapy monitoring**, lymphoma patients, FDG-PET, 156(ab)
- Chest**, acute pain injection, Tc-99m tetrofosmin liver clearance, effect of time, 155(ab)
- Children**, ictal perfusion brain SPECT in epilepsy, administration of ^{99m}Tc-bicisate by nurses, 219
- Chronic pain**, interacting with the terminally ill patient, strategies for the nuclear medicine technologies, 92
- Cisplatin**, effect on rodent kidney uptake, ^{99m}Tc-MDP, 132
- Clearance**, pathogens and autoantibodies, primate circulation, radionuclide imaging, bispecific-based therapies, 188(ab)
- Clinical imaging**, ACNP proficiency testing program, phantoms, 342
- Collimation**, high-resolution versus low-energy general-purpose, comparison in dual-isotope myocardial perfusion scans, 172(ab)
- Collimators**, lead, manufacture using electro discharge machining, 185(ab)
- Colorectal cancer**, In-111-MoAb-B72.3, SPECT/planar versus planar imaging, target-background ratio comparison, 155(ab)
- Competency**, professionalization in nuclear medicine technology, 336
- Computed tomography (CT)**, MRI, PET and SPECT versus, registration in clinical nuclear medicine environment, 157(ab)
- Computer network design**, designing, implementing and operating nuclear medicine picture archiving communications system, 329

- Computers**
description of medical resources on the Internet, part 4 of 4, 10
high tech media and role in education of student technologists, 242
Internet update since March JNMT, emphasis on nuclear medicine resources, 303
software, multimodality, test options, 184(ab)
Windows-based nuclear medicine network, image review/transfer/archiving, 167(ab)
- Constancy**, in dose calibrator performance, quality control testing, 124
- Coronary artery disease**, myocardial perfusion imaging, Tc-99m tetrofosmin PET, 172(ab)
- Creatinine**, 24-hour clearance, comparison with Tc-99mMAG3 derived GFR values, 160(ab)
- Cross-training**, nuclear medicine technologists, exercise treadmill testing, 172(ab)
- Curie, Marie**, and her contemporaries, accomplishments of, 273
- Cyclosporine A**, effect of, efficiency of ^{99m}Tc-RBC labeling procedure, 232
- Cystography**, radionuclide, hispanic girls, risk, 185(ab)
- Diagnostic radiopharmaceuticals**, radiation exposure to nurses, monitoring and safety issues, 45
- Dose calibrator**, quality control testing of, 124
- Dosimetry**
I-131 therapy and, papillary thyroid treatment prediction, 154(ab)
In-111 labeled monoclonal antibodies and quantitative imaging, 166(ab)
- Dual-isotope imaging**, simultaneous, parathyroidadenomas, 184(ab)
- Dysmotility**, function of esophagus in systemic sclerosis, use of scintigraphy for simplified imaging, semiquantitative grading system, 316
- Education**, imaging or SPECT instructional principles, computer illustration of optimum learning environment, 166(ab)
- Educational technology**, commentary of role in learning process of student technologists, 242
- Ejection fraction**
left ventricle
automated quantitation, gated myocardial infusion SPECT, 152(ab)
gated Tc-99m sestamibi, 152(ab)
semiautomatic quantification, gated planar Tc-99m MIBI myocardial perfusion scintigraphy, 183(ab)
- Electro discharge machining**, lead collimator manufacture, 185(ab)
- Employment**, education and job market, New England nuclear medicine technologists, 49
- Environmental protection agency**, exploration of the Clean Air Act for the nuclear medicine professional, 3
- Environmental radioactive releases**, dedicated system monitoring, 162(ab)
- Epilepsy**
detection of foci with FDG-PET, 23
ictal perfusion brain SPECT in pediatric patients, multidisciplinary approach, administration of ^{99m}Tc-bicisate by nurses, 219
seizure foci localization, coregistration of overlaid cerebral blood flow SPECT on MRI images, 160(ab)
- Epileptogenic**, ictal perfusion brain SPECT in children, multidisciplinary approach involving administration of ^{99m}Tc-bicisate by nurses, 219
- Esophageal scintigraphy**, simplified imaging and reporting method, systemic sclerosis, 316
- Ethics**, advantages of informed consent, guide for the nuclear medicine technologist, 129
- Ethylenediaminetetraacetic acid**, effects on labeling efficiency, Tc-99m RBC, UltraTag RBC kit, 186(ab)
- Extracardiac uptake**, normal and abnormal variants, ^{99m}Tc-MIBI, 103
- Fan beam collimators**, evaluation of alignment, multihead SPECT imaging, quality control, 314
- Fistulas**, arteriovenous, patency determination by radionuclide transit curve fitting, chronic hemodialysis patients, 160(ab)
- Flood field**, uniformity and linearity, camera/source alignment, quality control measurements, 158(ab)
- Fluorine-18**, PET, region of interest positioning, influence on varying standardized uptake values, 169(ab)
- Fluorine-18 FDG**
automated synthesis, volatile losses, 162(ab)
PET
abdomen and pelvis, technical improvements, 169(ab)
detection of epileptic foci, 23
pediatric brain imaging, benefits of three-dimensional acquisition, 157(ab)
whole-body studies, comparison with and without attenuation correction, 157(ab)
Tc-99m MIBI and, SPECT, ischemic myocardium detection, 156(ab)
use in evaluation of breast tumors, comparison to ^{99m}Tc-MIBI, 198
- Fourier analysis**, first harmonic, stress gated Tc-99m sestamibi myocardial perfusion SPECT, 172(ab)
- Frequency space domain**, cerebral perfusion SPECT, optimized filter, 164(ab)
- Furifosmin**, potential use as new myocardial perfusion imaging agent, 119
- Furosemide**, body imaging, FDG-PET, 168(ab)
- Gadolinium-153**
attenuation corrected myocardial SPECT, effect by Tc-99m increased hepatic activity, 173(ab)
photon attenuation correction, myocardial perfusion SPECT, effect of gated acquisition, 173(ab)
- Gallbladder fossa**, persistent bowel activity of, ⁶⁷Ga-citrate, case report of differential diagnosis, 230
- Gallium-67**, persistent bowel activity of, limitations on diagnosis of abdominal infections, 230
- Gamma camera**
dual-detector, total-body Tc-99m angiography, 173(ab)
triple-headed, multiple simultaneous uniformity correction acquisition, three-point-source technique, 158(ab)
Windows-based nuclear medicine network, image review/transfer/archiving, 167(ab)
- Gastric emptying**, solid phase, half-time measurements with two data points, 161(ab)
- Gastric emptying rate**, determination of, factors in labeling test meals, 227
- Gastrointestinal bleeding**, Tc-99m RBC labeling efficiency, effects of EDTA, UltraTag RBC kit, 186(ab)
- Generator technology**, effective use in 1990s, 245(1e)
- Geometry**, in dose calibrator performance, quality control testing, 124
- Glomerular filtration rate**, derived GFR from ^{99m}Tc-MAG3 data, correlation with 24-hour creatinine clearance, 223
- Grief**, interacting with the terminally ill patient, strategies for the nuclear medicine technologist, 92
- Guidelines**, nuclear cardiology training, survey of NMT educational programs, 55
- H. pylori**, detection, safe low-dose C-14 urea breath test, 160(ab)
- Heart**
SPECT reconstruction, phantom evaluation, 155(ab)
ventricular function, evaluation with Ir-191m, technical considerations, 174(ab)
- Hemodialysis**, arteriovenous fistula patency determination, radionuclide transit curve fitting, 160(ab)
- Hevesy, Georg Charles de**, father of nuclear medicine, scientific heritage, 291
- High-resolution imaging**, medium-energy radiopharmaceuticals, 157(ab)
- Hydrocephaly**, negative pressure, case report, 167(ab)
- Hyperperfusion**, chronic cerebral, effect on muscarinic cholinergic receptor binding, PET studies, rats, 162(ab)
- Ictal**, perfusion brain SPECT in children with intractable epilepsy, multidisciplinary approach involving administration of ^{99m}Tc-bicisate by nurses, 219
- Image intensity**, liposome concentration as function of, calibration, 186(ab)
- Image quality**, ACNP proficiency testing program, quality control, 342
- Indium-111**, labeled monoclonal antibodies, quantitative imaging and dosimetry, 166(ab)
- Indium-111 MoAb-B72.3**, SPECT/planar versus planar imaging, target-background ratio comparison, colorectal cancer, 155(ab)
- Indium-111 pentetretotide**, scintigraphy, suspected neuroendocrine tumors, normal variants and incidental findings, 167(ab)
- Infection**, case report of ⁶⁷Ga citrate simulating cholecystitis, persistent bowel activity, 230
- Informed consent**, legal, ethical, and therapeutic advantages of, 129
- Internet**
description of medical resources, means of locating information, part 4 of 4, 10
update since March JNMT, World Wide Web, 303
- Intranasal midazolam**, comparison of spray to drops for pediatric patients, 32
- Iodine-131**
papillary thyroid treatment prediction, calculated dosimetry and, 154(ab)

- therapy, neck/thigh ratios, hyperthyroid patient evaluation with Tc-99m pertechnetate, 169(ab)
- whole-body scan, nasal hot spot appearance, physiological uptake variation, 112
- Iridium-191m**, ventricular function evaluation, technical considerations, 174(ab)
- Kidney**, function, Tc-99m MAG3 ERPF quantitation, product of plasma volume and renal uptake, 161(ab)
- Labeling efficiency**, effect of cyclosporine on ^{99m}Tc-RBC labeling procedure, 232
- Labeling stability**, factors involved with determining gastric emptying rate, test meals, 227
- Lactulose**, breath testing, manometry and, comparison with small-bowel transit scintigraphy, 161(ab)
- Law**, legal, ethical, and therapeutic benefits of informed consent, 129
- Linearity**, in dose calibrator performance, quality control testing, 124
- Liposomes**, concentration calibration, function of image density, 186(ab)
- Liver**
increase activity, inferior wall artifact and, attenuation correction, 156(ab)
Tc-99m tetrofosmin clearance, effect of time, after acute chest pain injection, 155(ab)
- Lung**
nodule evaluation, Tc-99m sestamibi, ratio techniques, 171(ab)
quantitative scans, Xe-133, 171(ab)
quantitative SPECT, volume reduction surgery and, 187(ab)
shunt, MAA particle size evaluation, 165(ab)
Tc-99m MAA perfusion imaging, anterior oblique and lateral views, diagnostic utility comparison, 187(ab)
- Lyme disease**, assessment by SPECT cerebral blood flow imaging, 159(ab)
- Lymphoma**
case report of ⁶⁷Ga citrate simulating cholecystitis, persistent bowel activity, 230
chemotherapy monitoring, FDG-PET, 156(ab)
- Lymphoscintigraphy**, Tc-99m sulfur colloid, optimized preparation, 154(ab)
- Magnetic resonance imaging (MRI)**
coregistration of overlaid cerebral blood flow SPECT images, epileptic seizure foci localization, 160(ab)
CT and, PET and SPECT versus, registration in clinical nuclear medicine environment, 157(ab)
- Manometry**, lactulose breath testing and, comparison with small bowel transit scintigraphy, 161(ab)
- Minimum and maximum allowance**, determining optimal pediatric dosage, nuclear medicine diagnostics, 35
- Misadministration**, patient and sample identification, bar code system for blood radiology, 39
- Monitoring**, environmental radioactive releases, dedicated system, 162(ab)
- Monoclonal antibodies**, In-111 labeled, quantitative imaging and dosimetry, 166(ab)
- Multicredentialed**, employment and education, study of nuclear medicine technologists in New England, 49
- Multidisciplinary**, ictal perfusion brain SPECT in pediatric patients with seizures, administration of ^{99m}Tc-bicisate by nursing staff, 219
- Multimodality**, software, exploring test options, 184(ab)
- Multiskilled**, education and job market, New England nuclear medicine technologists, 49
- Myocardial infarction**, gated infusion SPECT, left ventricular ejection fraction, automated quantitation, 152(ab)
- Myocardial perfusion**
dual-isotope, high-resolution versus low-energy general-purpose collimation, 172(ab)
elastic matching to template, 164(ab)
gated planar Tc-99m MIBI scintigraphy, ejection fraction semiautomatic quantification, 183(ab)
SPECT
effect of gated acquisition, photon attenuation correction, Gd-153source, 173(ab)
manual versus automatic quantitative analysis, 173(ab)
stress gated Tc-99m sestamibi SPECT, first harmonic Fourier analysis, 172(ab)
Tc-99m tetrofosmin PET, coronary artery disease diagnosis, 172(ab)
- Myocardial perfusion imaging**, potential use of new ^{99m}Tc-labeled agents, tetrofosmin, furifosmin, NOET, 119
- Nasal secretion**, ¹³¹I accumulation in mucous, physiological uptake variation in whole-body scanning, 112
- Network**
description of medical resources on the Internet, part 4 of 4, 10
Internet update since March JNMT, World Wide Web, computer resources, 303
- Neuroendocrine tumors**
In-111 scintigraphy, normal variants and incidental findings, 167(ab)
somatostatin receptor scintigraphy, octreoscan and, patient management, 167(ab)
- NOET**, potential use as new myocardial perfusion imaging agent, 119
- Normal variants**, extracardiac uptake of ^{99m}Tc-MIBI, 103
- Nuclear cardiology**, guidelines for training, survey of NMT educational programs, 55
- Nuclear medicine**, early experience in application of artificial radioactivity to medicine, 270
- Nuclear medicine sites**
Internet update since March JNMT, computer resources, 303
introduction to the Internet for nuclear medicine professionals, part 4 of 4, 10
- Nuclear regulations**, declared pregnant woman, standards for protection, 83
- Occupational radiation exposure**, standards for protection in nuclear medicine, declared pregnant woman, 83
- Octreoscan**, somatostatin receptor scintigraphy, patient management, neuroendocrine tumors, 167(ab)
- Oncology**, ECAT ART, dynamic/static/whole-body imaging, 163(ab)
- Osteoarthritis**, Tc-99m MDP bone imaging, low dose, 160(ab)
- Oxygen-15 water**, automatic synthesis and administration unit, multiple intravenous injection, 163(ab)
- PACS**, *see* Picture archiving communications system,
- Parathyroid**, adenomas, simultaneous dual isotope imaging, 184(ab)
- Parkinson's disease**, experimental, SPECT, 162(ab)
- Part 20**, NRC's rules and regulations, calculation and prevention of radionuclide intake, volatile substances, 204
- Pathogens**, autoantibodies and, primate circulation clearance, radionuclide imaging, bispecific-based therapies, 188(ab)
- Patient communication**, legal, ethical, and therapeutic benefits of informed consent, 129
- Patient fear**, addressing patients emotional needs, undiagnosed symptoms, 325
- Pediatric dosage**, determining optimal radiopharmaceutical amounts, 35
- Pediatric sedation**, comparison of midazolam nasal spray to nasal drops, 32
- Phantoms**, simulation of clinical imaging, proficiency testing program ACNP, 342
- Picture archiving communications system**, review of designing, implementing, and operating process, computer network design, 329
- Point source**, scintillation camera preparation, abetter way, 186(ab)
- Positive patient identification**, blood radiolabeling procedures with a bar code system, 39
- Positive sample identification**, blood radiolabeling procedures with a bar code system, 39
- Positron emission tomography (PET)**
carbon-11 β -CNT, biodistribution, mice, 184(ab)
carbon-11 distribution, autoactivation of C-12 beams in heavy ion therapy, 167(ab)
chronic cerebral hyperfusion, effect on muscarinic cholinergic receptor binding, rats, 162(ab)
flourine-18 FDG
abdomen and pelvis, technical improvements, 169(ab)
chemotherapy monitoring, lymphoma patients, 156(ab)
furosemide use in body imaging, 168(ab)
improved detection of epileptic foci, 18F-FDG, 23
pediatric brain imaging, benefits of three-dimensional acquisition, 157(ab)
pediatric patients, sedation and, 171(ab)
region of interest positioning, influence on varying standardized uptake values, 169(ab)
whole-body imaging, artifact reduction and, techniques, 169(ab)
whole-body studies, comparison with and without attenuation correction, 157(ab)
SPECT and, CT and MRI versus, registration in clinical nuclear medicine environment, 157(ab)
- Professionalization**, in nuclear medicine technology, competency beyond task performance, 336
- Proficiency testing**, ACNP program, quality control, 342

- Proficiency testing program**, complement to a nuclear departments quality assurance program, phantoms, 342
- Prostate**, cancer diagnosis, PSA test and bone imaging correlation, 169(ab)
- Prout, William**, and others, humble beginnings of nuclear medicine discoveries, 280
- Qualitative research**, professionalization in nuclear medicine technology, competency, 336
- Quality control**
ACNP proficiency testing program, phantoms, 342
artifacts on pinhole thyroid images, collimator shielding defects, 27
measurements, accurate and reproducible camera/source alignment, 158(ab)
method of rapid confirmation of radiochemical purity, ^{99m}Tc-MIBI, 114
syringe filter method, ^{99m}Tc-MAA preparation, 236
Tc-99m tetrofosmin, rapid chromatographic procedure, 165(ab)
testing for accuracy, linearity, constancy, and geometry dependence of dose calibrators, 124
- Radiation exposure of nurses**, use of diagnostic radiopharmaceuticals, radiation safety and monitoring, 45
- Radiation monitoring**, radiopharmaceutical exposure to nurses, safety issues, 45
- Radiation safety**
radiation exposure to nurses, monitoring trends, 45
standards for protection in nuclear medicine, declared pregnant woman, 83
- Radiochemical purity**, rapid quality control of ^{99m}Tc-MIBI, 114
- Radiologic science professionals**, pilot study of chemical substance use, 59
- Radionuclide emissions**, analysis of the Clean Air Act, impact on nuclear medicine professionals, 3
- Radionuclide intake**, calculation and prevention of, NRC's rules and regulations, Part 20, volatility, 204
- Radionuclide venography**, lower extremities and pelvis, computer acquisition and display technique, 166(ab)
- Radiopharmaceuticals**
medium-energy, high-resolution imaging, 157(ab)
nuclear pharmacy, radiopharmaceutical dispensing trends, 165(ab)
- Red blood cells**
labeling efficiency evaluation, methods of several manufacturers, 173(ab)
modified in vivo preparation method, 153(ab)
- Region of interest**
analysis, differentiation of benign/pre-malignant/malignant breast conditions, 154(ab)
positioning, F-18 PET, influence on varying standardized uptake values, 169(ab)
- Renal imaging**, effect of full bladder on, ^{99m}Tc-DTPA, 321
- Renal plasma flow**, derived GFR from ^{99m}Tc-MAG3 data, correlation with 24-hour creatinine clearance, 223
- Renal transplant**, effect of full bladder on renal imaging, ^{99m}Tc-DTPA, 321
- Rutherford, Ernest**, accomplishments of, Marie Curie and her contemporaries, 273
- Scintigraphy**
bone, optimal, 160(ab)
gated planar Tc-99m MIBI myocardial perfusion, ejection fraction semiautomatic quantification, 183(ab)
In-111 scintigraphy, suspected neuroendocrine tumors, normal variants and incidental findings, 167(ab)
small-bowel transit, new methods of measurement, comparison to lactulose breath testing and manometry, 161(ab)
- Scintimammography**
dynamic Tc-99m MDP, factor analysis application, 187(ab)
lateral decubitus positioning in diagnosis of breast cancer, ²⁰¹Tl, 213
Tc-99m MIBI, early and delayed imaging comparison, 185(ab)
Tc-99m sestamibi prone, positioning cushion use, primary breast cancer detection, 168(ab)
- Semiquantitation**, grading system for reporting degree of dysmotility, esophageal scintigraphy in patient with systemic sclerosis, 316
- Shunts**, pulmonary, MAA particle size evaluation, 165(ab)
- Single-photon emission computed tomography (SPECT)**
blood-pool imaging, planar studies and, 152(ab)
bone, 180° versus 360°, faster acquisition, 184(ab)
brain
attenuation correction, simultaneous acquisition of transmission and emission data, 160(ab)
differential magnification during acquisition, 159(ab)
cardiac reconstruction, phantom evaluation, 155(ab)
cerebral blood flow
coregistration of overlaid MRI images, epileptic seizure foci localization, 160(ab)
imaging, CNS Lyme disease assessment, 159(ab)
statistical mapping by three-dimensional stereotactic surface projection, 159(ab)
cerebral perfusion, frequency space domain, optimized filter, 164(ab)
experimental Parkinson's disease, 162(ab)
flourine-18 FDG and Tc-99m MIBI, ischemic myocardium detection, 156(ab)
gated cardiac Tc-99m MIBI, wall thickening and motion evaluation, normal volunteers, 163(ab)
gated myocardial infusion, left ventricular ejection fraction, automated quantitation, 152(ab)
instructional principles, computer illustration of optimum learning environment, 166(ab)
myocardial gated Tc-99m sestamibi, myocardial contractility analysis, 164(ab)
myocardial perfusion
attenuation correction, 180° versus 360° reconstructions, 153(ab)
effect of gated acquisition, photon attenuation correction, Gd-153source, 173(ab)
manual versus automatic quantitative analysis, 173(ab)
technetium-99m sestamibi, quantitative two-day, trial validation, 158(ab)
- PET and, CT and MRI versus, registration in clinical nuclear medicine environment, 157(ab)
quantitative lung, volume reduction surgery and, 187(ab)
SPECT/planar versus planar imaging alone, target-background ratio comparison, colorectal cancer, In-111 MoAb-B72.3, 155(ab)
stress gated Tc-99m sestamibi myocardial perfusion, first harmonic Fourier analysis, 172(ab)
Tc-99m HMPAO, brain, utility of normative data, 159(ab)
Tc-99m MAA, lung, non-uniform attenuation correction, 161(ab)
TI-201, left ventricular dilatation index, gender-matched normal files, 153(ab)
- Somatostatin**, receptor scintigraphy, octreoscan and, patient management, neuroendocrine tumors, 167(ab)
- SPECT**, cervical spine imaging, ANG versus NOR technique, 100
- SPECT quality control**, evaluation of fanbeam collimator alignment, multihead imaging, 314
- Spina bifida**, negative pressure hydrocephaly, case report, 167(ab)
- Stannous ion**, effect of cyclosporine on labeling of red blood cells, 232
- Student technologists**, commentary on education of, high-tech media, 242
- Surgery**, lung, volume reduction, quantitative SPECT and, 187(ab)
- Syringe filter**, quality control analysis of ^{99m}Tc-MAA preparations, 236
- Systemic sclerosis**, esophageal scintigraphy as standard clinical tool, semiquantitative grading system, UGI dysmotility, 316
- Technetium-99m bicisate**, ictal perfusion brain SPECT in children with epilepsy, multidisciplinary approach, 219
- Technetium-99m colloid**, factors in labeling test meals, determining gastric emptying rate, 227
- Technetium-99m DTPA**
effect of full bladder of renal imaging, technical pitfall, 321
factors in labeling test meals, determining gastric emptying rate, 227
- Technetium-99m HMPAO**
brain SPECT, utility of normative data, 159(ab)
labeled white blood cells, inflammatory bowel disease diagnosis, 160(ab)
- Technetium-99m MAA**
lung perfusion imaging, anterior oblique and lateral views, diagnostic utility comparison, 187(ab)
perfusion lung SPECT, nonuniform attenuation correction, 161(ab)
syringe filter method for quality control of, 236
- Technetium-99m MAG3**
derived GFR values, comparison with 24-hour creatinine clearance, 170(ab)
derived GFR values, comparison with 24-hour creatinine clearance, 223
ERPF quantitation, product of plasma volume and renal uptake, 161(ab)
- Technetium-99m MDP**
bone imaging, low-dose, osteoarthritis, 160(ab)

- effect of cisplatin on rodent kidney uptake, 132
- scintimammography, factor analysis application, 187(ab)
- Tc-99m labeled synthetic peptide and, breast cancer imaging, acquisition protocol, 168(ab)
- total-body blood-pool and, value for delayed total-body bone scans, 160(ab)
- Technetium-99m-MIBI**, normal and abnormal variants of extracardiac uptake, 103
- Technetium-99m P280**
- active clot formation evaluation, clinical experience/quality control/optimal imaging parameters, 32 suspected deep vein thrombosis cases, 171(ab)
 - radionuclide venogram and blood pool imaging, complementary roll to thromboscintigram, 157(ab)
- Technetium-99m-pertechnetate**, neck/thigh ratios for subsequent I-131 therapy, hyperthyroid patient evaluation, 169(ab)
- Technetium-99m-RBC**
- labeling efficiency
 - effects of EDTA on, UltraTag RBC kit, 186(ab)
 - study of sequential factors using Ultra-Tag, 165(ab)
 - Tc-99m sulfur colloid and, hepatic anatomy and hemangioma location, three-dimensional varying threshold technique, 158(ab)
 - labeled red blood cells
 - labeling efficiency evaluation, methods of several manufacturers, 173(ab)
 - modified in vivo preparation method, 153(ab)
- Technetium-99m sestamibi**
- breast cancer, diagnosis, 187(ab)
 - breast images, semi-quantitative analysis, utility and reproducibility, 154(ab)
 - breast tumor scintigraphy as adjunctive diagnostic tool, 198
- F-18 FDG and, SPECT, ischemic myocardium detection, 156(ab)
- gated cardiac SPECT, wall thickening and motion evaluation, normal volunteers, 163(ab)
- gated planar myocardial perfusion scintigraphy, ejection fraction semiautomatic quantification, 183(ab)
- left ventricular ejection fraction, 152(ab)
- lung nodule evaluation, ratio techniques, 171(ab)
- myocardial gated SPECT, myocardial contractility analysis, 164(ab)
- myocardial SPECT, quantitative two-day, trial validation, 158(ab)
- prone scintimammography, positioning cushion use, primary breast cancer, 168(ab)
- rapid quality control, confirmation of radiochemical, 114
- scintimammography, early and delayed imaging comparison, 185(ab)
- stress gated myocardial perfusion SPECT, first harmonic Fourier analysis, 172(ab)
- uptake comparison, during arbutamine infusion versus exercise stress, 183(ab)
- Technetium-99m sulfur colloid**, optimized preparation, lymphoscintigraphy, 154(ab)
- Technetium-99m tetrofosmin**
- formulation alteration, effect on preparation purity and stability, 164(ab)
 - liver clearance, effect of time, after acute chest pain injection, 155(ab)
 - PET, myocardial perfusion, coronary artery disease diagnosis, 172(ab)
 - quality control, rapid chromatographic procedure, 165(ab)
- Technetium-99m-NOET**, potential use as a new myocardial imaging agent, 119
- Technologist education**, credentials and job market in nuclear medicine, New England, 49
- Terminal illness**, interacting with the dying patients, strategies for the nuclear medicine technologist, 92
- Tetrofosmin**, potential use as new myocardial perfusion imaging agent, 119
- Thallium-201**
- scintimammography in diagnosis of breast cancer, lateral decubitus positioning, 213
 - SPECT, left ventricular dilatation index, gender-matched normal files, 153(ab)
 - use in evaluation of breast tumors, comparisons to ^{99m}Tc-MIBI, 198
- Therapeutic approaches**, patient fear, addressing patients emotional needs within nuclear medicine department, 325
- Three-dimensional stereotactic surface projection**, statistical mapping, cerebral blood flow SPECT, 159(ab)
- Thromboscintigram**, Tc-99m P280 radionuclide venogram and blood pool imaging, complementary roles, 157(ab)
- Thrombosis**, deep vein, Tc-99m P280 in active clot formation evaluation, 32 cases, 171(ab)
- Thyroid cancer**, nasal hot spot appearance after ¹³¹I whole-body scanning, false-positive uptake, 112
- Thyroid imaging**, quality control for artifacts, collimator shielding defects, 27
- Training**, nuclear cardiology guidelines, survey of NMT educational programs, 55
- Tumor detection**, colorectal cancer, SPECT/planar versus planar In-111 MoAb-B72.3 imaging, target-background ratio comparison, 155(ab)
- Ultra-Tag**, study of sequential factors, Tc-99m RBC labeling efficiency, 165(ab)
- Undiagnosed symptoms**, patient fear, interpersonal approach within nuclear medicine department, 325
- Uniformity correction**, multiple simultaneous acquisition, triple-headed gamma camera, three-point-source technique, 158(ab)
- Venogram**, radionuclide, blood pool imaging and, Tc-99m-P280, complementary role to thromboscintigram, 157(ab)
- Venography**, radionuclide, lower extremities and pelvis, computer acquisition and display technique, 166(ab)
- Vesicoureteral reflux**, radionuclide cystography, hispanic girls, risk, 185(ab)
- White blood cells**, Tc-99m HMPAO labeled, inflammatory bowel disease diagnosis, 160(ab)
- Wide-area networks**, nuclear medicine picture archiving communications system, 329
- World Wide Web**
- Internet update since March JNMT, computer resources, nuclear medicine, 303
 - introduction to the Internet for nuclear medicine professionals, part 4 of 4, 10
- Xenon-133**, quantitative lung scans, 171(ab)